Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors

Authors
Vuky, J McCaffrey, J Ginsberg, M Mariani, T Bajorin, DF Bosl, GJ Motzer, RJ
Citation
J. Vuky et al., Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors, INV NEW DR, 18(3), 2000, pp. 265-267
Citations number
9
Categorie Soggetti
Pharmacology,"Pharmacology & Toxicology
Journal title
INVESTIGATIONAL NEW DRUGS
ISSN journal
01676997 → ACNP
Volume
18
Issue
3
Year of publication
2000
Pages
265 - 267
Database
ISI
SICI code
0167-6997(200008)18:3<265:PITOPI>2.0.ZU;2-K
Abstract
Thirteen patients with cisplatin-refractory germ cell tumors were treated o n a Phase II trial with pyrazoloacridine. Pyrazoloacridine was given intrav enously at 600 mg/m(3) every three weeks. The median nadir leucocyte count was 2.5 cells/mm(3), hemoglobin was 10.8 g/dl, and platelet count was 126,0 00 cells/m(3). None of the thirteen evaluable patients achieved a major res ponse. Pyrazoloacridine is not efficacious in the treatment of cisplatin-re fractory germ cell tumors.